Sangamo BioSciences recently presented data supporting SB-525 at the 58th Annual Meeting of the American Society of Hematology (ASH), which was held Dec. 3-6 in San Diego, California.
"We have developed an improved gene therapy vector for treatment of hemophilia A, which we believe is highly competitive, and we remain on track to file an Investigational New Drug (IND) application for our clinical program by the end of 2016," Sangamo President and CEO Sandy Macrae said.
The data presented on SB-525 included preclinical and manufacturing data that supports its gene therapy program for hemophilia A.
"This program illustrates Sangamo's drug development capabilities beyond our ZFP platform," Macrae said. "Moreover, it demonstrates the ability of our R&D and technical operations teams to rapidly develop a program from research data, through positive preclinical results in relevant animal models to a clinical program fully supported by a scalable manufacturing process. We have strengthened our clinical development capabilities with recent senior management changes and are committed to consistent achievement of planned milestones for our four clinical programs. We look forward to initiating a clinical trial in 2017 to evaluate SB-525."
Sanagamo BioSciences is a leader in the editing of therapeutic genome.
